Scopolamine
AnticholinergicsOther antiemeticsOther hypnotics and sedativesAnticholinergicCholinergic AntagonistsCholinergic Muscarinic AntagonistsHistamine H1 Receptor AntagonistsSerotonin AntagonistsDecreased GI MotilityDecreased Histamine ActivityDecreased Nasal and Sinus SecretionsDecreased Parasympathetic Acetylcholine ActivityDecreased Serotonin ActivityPositive ChronotropyPupillary DilationSalivation InhibitionUS-FDASourced from openFDA
GET
/api/v1/drug/scopolamineMechanism of action
Sourced from openFDAMechanism-of-action classes: Cholinergic Antagonists; Cholinergic Muscarinic Antagonists; Histamine H1 Receptor Antagonists; Serotonin Antagonists.
CholinergicCholinergic MuscarinicHistamine H1 ReceptorSerotonin
Approval history
Sourced from openFDA- Dec 31, 1979NDANDA017874Baxter Hlthcare Corp
- Jan 30, 2015ANDAANDA078830Padagis Us
- Jun 19, 2019ANDAANDA203753Mylan Technologies
- Nov 24, 2020ANDAANDA212342Riconpharma Llc
- Jan 10, 2022ANDAANDA208769Actavis Labs Ut Inc
- May 6, 2024ANDAANDA215329Rhodes Pharms
- Aug 29, 2024ANDAANDA217893Zydus Pharms
- Jun 9, 2025ANDAANDA218384Amneal
FDA shortages
Reference statistics from the openFDA drug-shortage dataset. For a live view, consult the FDA database directly. Not clinical guidance.
- Scopolamine, Transdermal System, 1 mg (NDC 45802-580-46)To be discontinuedSponsor: Padagis US LLCUpdated
FAERS reports
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
6,683 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
- 1Nausea79112%
- 2Off Label Use68710%
- 3Vomiting5428.1%
- 4Dizziness5267.9%
- 5Drug Ineffective4176.2%
- 6Headache3986.0%
- 7Fatigue3395.1%
- 8Diarrhoea3204.8%
- 9Pain3194.8%
- 10Vision Blurred3104.6%
- 11Malaise2904.3%
- 12Confusional State2593.9%
- 13Product Adhesion Issue2593.9%
- 14Death2583.9%
- 15Dyspnoea2483.7%
Literature
Recent PubMed references pinned to Scopolamine as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.
- Sexual dimorphism and photoperiodism in cognitive and neuronal ionic changes in scopolamine-induced cognitive impairment.Metabolic brain disease · 2026 · Abdulkadir TS, Ayo JO, Isa AS, et al.PMID 42201435DOI 10.1007/s11011-026-01890-0
- Ziziphus jujuba Mill. Suspension Ameliorates Scopolamine-Induced Cognitive Impairment via PTGS2-Centered Neuroinflammatory Signaling.Mediators of inflammation · 2026 · Liu Q, Wang Y, Wang B, et al.PMID 42093362DOI 10.1155/mi/8871660
- Protective Effects of a Propolis-Petasites japonicus Mixture on Scopolamine-Induced Memory Impairment in Mice.Journal of microbiology and biotechnology · 2026 · Kim MY, Shin JY, Lim JH, et al.PMID 42049692DOI 10.4014/jmb.2602.02019
- Comparison of the effect of donepezil and a combination of donepezil and mefloquine (THN201) on cognition during a scopolamine challenge in healthy participants.Experimental and clinical psychopharmacology · 2026 · Dondaine T, Rein W, Micallef J, et al.PMID 41989444DOI 10.1037/pha0000825
- Exploring the Evolving Role of Scopolamine in Pharmacotherapy: From Cognitive Impairment to Neuroplasticity?-A Narrative Review.Molecules (Basel, Switzerland) · 2026 · Kukla J, Olejnik P, Kasarełło K, et al.PMID 41976259DOI 10.3390/molecules31071219
- Increase in BACE1 Phosphorylation in the Rat Hippocampus and Phytosphingosine in Plasma After Chronic Administration of Scopolamine.International journal of molecular sciences · 2026 · Velazquez Toledano J, Guerrero González I, Pacheco-Yépez J, et al.PMID 41828465DOI 10.3390/ijms27052241
- Hyperforin Attenuates Scopolamine Induced Alzheimer's Pathology in Rat Model: Abrogation of Caspase-1/11 Mediated Pyroptosis via Inhibition of HMGB1-Mediated RAGE Pathway.Journal of biochemical and molecular toxicology · 2026 · Chen Y, Zhao X, Kassab RB, et al.PMID 41766189DOI 10.1002/jbt.70753
- Targeted transdermal scopolamine delivery over the salivary glands for sialorrhea: Dose-response and systemic safety in rats.Journal of pharmaceutical sciences · 2026 · Ishida N, Takagaki K, Urayama M, et al.PMID 41698480DOI 10.1016/j.xphs.2026.104209
Clinical trials
The 10 most recently updated of 446 ClinicalTrials.gov registrations naming Scopolamine as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- Oral Hyoscine vs Lidocaine-Prilocaine Spray vs Placebo for HSG Pain ReliefCompleted · Interventional · 102 enrolled · Cairo UniversityNCT07383571updated 2026-06-11
- Imaging of Endometriosis With Total-body PET-CT (PET-Endo)Recruiting · Observational · 30 enrolled · University of EdinburghNCT07523997updated 2026-05-27
- Multimodal Analgesia vs. Routine Care Pain Management for Lumbar Spine Fusion Surgery: A Prospective Randomized StudyTerminated · Phase 4 · Interventional · 50 enrolled · OrthoCarolina Research Institute, Inc.NCT02202369updated 2026-05-22
- Anesthetic Optimization in Pediatric LeFort SurgeriesRecruiting · Interventional · 50 enrolled · Johns Hopkins UniversityNCT05260320updated 2026-05-20
- ERAS Protocols in Breast Conserving SurgeryRecruiting · Interventional · 260 enrolled · University of NebraskaNCT06938581updated 2026-05-19
- Multimodal Anesthesia in Robotic Laparoscopic NephrectomyNot yet recruiting · Interventional · 80 enrolled · Fundacio PuigvertNCT07558226updated 2026-04-30
- Representation of Spatiotemporal Information in Human Episodic Memory and NavigationEnrolling by invitation · Early phase 1 · Interventional · 15 enrolled · University of ArizonaNCT07423923updated 2026-04-30
- Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPDSuspended · Interventional · 100 enrolled · Medical University of BialystokNCT07541378updated 2026-04-21
- Valethamate Bromide Versus Hyoscine Butyl Bromide in Reducing Labour Duration Among PrimigravidaCompleted · Interventional · 165 enrolled · Federal Teaching Hospital AbakalikiNCT07474350updated 2026-03-16
- A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult SubjectsRecruiting · Phase 1 · Interventional · 57 enrolled · Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.NCT07267130updated 2026-03-10
Frequently asked questions
- How does Scopolamine work?
- Mechanism-of-action classes: Cholinergic Antagonists; Cholinergic Muscarinic Antagonists; Histamine H1 Receptor Antagonists; Serotonin Antagonists.
- What class of drug is Scopolamine?
- Scopolamine is classified as Anticholinergics, Other antiemetics, Other hypnotics and sedatives, Anticholinergic, Cholinergic Antagonists, Cholinergic Muscarinic Antagonists, Histamine H1 Receptor Antagonists, Serotonin Antagonists, Decreased GI Motility, Decreased Histamine Activity, Decreased Nasal and Sinus Secretions, Decreased Parasympathetic Acetylcholine Activity, Decreased Serotonin Activity, Positive Chronotropy, Pupillary Dilation, Salivation Inhibition.
- What are the brand names for Scopolamine?
- Scopolamine is marketed under brand names including Donnatal, Phenohytro, Transderm Scop.
Note. Data for
scopolamine is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.